Table 1 Demographics and clinical characteristics of patients with lack of efficacy of subcutaneous tocilizumab
Date of diagnosis | Etiology | Previous treatment | BMI (kg/m2) | Cortico-steroid dose at time of SC TCZ relapse | Time to relapse | Relapse characteristics | Time to efficacy | End of follow up after IV TCZ | Cortico-steroid dose at the end of follow-up | |
|---|---|---|---|---|---|---|---|---|---|---|
Case n°1 | 2014 | Birdshot | Methyl-prednisolone, interferon α2a, infliximab, tocilizumab IV | 37.8 | 10 mg | 4 months | Papillary edema, scotoma LE | 3 months | 61 months | 0 mg |
Case n°2 | 2017 | Birdshot | Prednisone, MMF, adalimumab | 27 | 10 mg | 6 months | Papillary edema, scotoma OU | 3 months | 12 months | 8 mg |
Case n°3 | 2019 | Behçet | Methyl-prednisolone, infliximab, adalimumab | 36.4 | 20 mg | 3 months | Macular edema OU | 3 months | 31 months | 0 mg |
Case n°4 | 2017 | Idiopathic | Prednisone, MTX | 46.3 | 10 mg | 5 months | Retinal vasculitis OU | 2 months | 18 months | 5 mg |